Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year
(MedPage Today) -- Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for pre-exposure prophylaxis (PrEP), according...
A year-long extension of the PURPOSE 1 and PURPOSE 2 trials testing lenacapavir, an injectable long-acting HIV pre-exposure prophylaxis (PrEP) medication, showed that only one new HIV infection occurred among over 4,700 participants. No new HIV cases were reported in the adolescent girls and young women extension in South Africa and Uganda, while only one new case was observed in the cisgender men and transgender or gender-nonbinary participants extension in Argentina.
The overall HIV incidence rate for both groups was 0.06 per 100 person-years, with injection-site reactions causing treatment discontinuation in less than 1% of participants in both trials.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
